For decades, Pharma juggernauts have been facing the challenge of patent cliffs for their blockbuster drugs. In light of the intense competition offered by generics, Big Pharma is exploring a plethora of LCM strategies to overcome the impact of patent expiry and consolidate their market position.  In this compendium we lay out five imperatives that establish the backbone of any follow-on product strategy and make it worthwhile to pursue along with live real-time case studies.

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now